Table 4.
Baseline characteristics and follow-up information of the corticosteroid users with SAEs group and non-SAEs group
| Baseline characteristic | SAEs group (n = 46, 12.5%) | Non-SAEs group (n = 323, 87.5%) | P value |
|---|---|---|---|
| Male (n [%])/female (n) | 24 (52.2)/22 | 180 (54.9)/148 | 0.730 |
| Age (yr) | 42 ± 13 | 33 ± 13 | <0.001 |
| Initial dosage of corticosteroid (mg/d) | 46 ± 9 | 46 ± 10 | 0.784 |
| Corticosteroid pulse | 8 (17.4) | 40 (12.4) | 0.345 |
| Reuse of corticosteroid | 9 (19.6) | 35 (10.8) | 0.087 |
| Corticosteroid plus immunosuppressant | 33 (71.7) | 186 (57.6) | 0.067 |
| Cyclophosphamide | 27 (58.7) | 143 (44.3) | |
| Tacrolimus | 4 (8.7) | 10 (3.1) | |
| Leflunomide | 4 (8.7) | 20 (6.2) | |
| Mycophenolate mofetil | 5 (10.9) | 15 (4.6) | |
| Cyclosporine A | 7 (15.2) | 24 (7.4) | |
| Systolic BP (mm Hg) | 132 ± 16 | 124 ± 16 | 0.001 |
| Diastolic BP (mm Hg) | 83 ± 9 | 79 ± 12 | 0.067 |
| Mean arterial pressure (mm Hg) | 99 ± 10 | 94 ± 12 | 0.010 |
| Serum creatinine (mmol/l) | 123 (81–178) | 103 (79–142) | 0.084 |
| Proteinuria (g/24 h) | 3.2 (1.9–6.7) | 3.0 (1.7–5.2) | 0.291 |
| eGFR (ml/min per 1.73 m2) | 60 ± 30 | 75 ± 33 | 0.003 |
| Uric acid (μmol/l) | 401 ± 113 | 385 ± 100 | 0.334 |
| Hemoglobin (g/l) | 130 ± 22 | 133 ± 20 | 0.232 |
| Albumin (g/l) | 33 ± 8 | 35 ± 8 | 0.267 |
| Triglyceride (mmol/l) | 2.4 ± 1.5 | 2.1 ± 1.5 | 0.444 |
| Total cholesterol (mmol/l) | 6.1 ± 2.6 | 5.9 ± 2.0 | 0.702 |
| Follow-up (mo) | 35 (12–74) | 49 (27–86) | 0.016 |
| ESRD | 14 (30.4) | 41 (12.7) | 0.010 |
| CKD stage | |||
| 1 | 8 (6.9) | 108 (93.1) | 0.006 |
| 2 | 13 (12.0) | 95 (88.0) | |
| 3 | 18 (15.5) | 98 (84.5) | |
| 4/5 | 7 (24.1) | 22 (75.9) |
Unless otherwise indicated values are n (%), means ± SDs, or median (25th–75th centiles). Bold values are statistically significant.
BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; SAEs, severe adverse effects.